Cornelius E Golding Net Worth

The estimated Net Worth of Cornelius E Golding is at least $1.75 Mille dollars as of 19 November 2014. Cornelius Golding owns over 2,000 units of Retrophin stock worth over $1,750 and over the last 11 years Cornelius sold RTRX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Cornelius Golding RTRX stock SEC Form 4 insiders trading

Cornelius has made over 2 trades of the Retrophin stock since 2013, according to the Form 4 filled with the SEC. Most recently Cornelius bought 2,000 units of RTRX stock worth $18,000 on 19 November 2014.

The largest trade Cornelius's ever made was buying 3,000 units of Retrophin stock on 6 December 2013 worth over $22,500. On average, Cornelius trades about 1,000 units every 70 days since 2013. As of 19 November 2014 Cornelius still owns at least 25,000 units of Retrophin stock.

You can see the complete history of Cornelius Golding stock trades at the bottom of the page.

What's Cornelius Golding's mailing address?

Cornelius's mailing address filed with the SEC is C/O RETROPHIN, INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK, NY, 10017.

Insiders trading at Retrophin

Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer e Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.

What does Retrophin do?

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Complete history of Cornelius Golding stock trades at Retrophin

Retrophin executives and stock owners

Retrophin executives and other stock owners filed with the SEC include:

• Eric Dube,
  President, Chief Executive Officer, Director
• Elizabeth Reed,
  Senior Vice President, General Counsel and Corporate Secretary
• Noah Rosenberg,
  Chief Medical Officer
• Peter Heerma,
  Chief Commercial Officer
• William Rote,
  Senior Vice President and Head of Research and Development
• Laura Clague,
  Chief Financial Officer, Senior Vice President
• Stephen Aselage,
  Director
• Sandra Poole,
  Independent Director
• Gary Lyons,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• Jeffrey Meckler,
  Independent Director
• John Orwin,
  Independent Director
• Roy Baynes,
  Independent Director
• Ron Squarer,
  Independent Director
• Suzanne Bruhn,
  Independent Director
• Neil F. Mc Farlane,
  Chief Operating Officer
• Jensen Margaret E Valeur,
  General Counsel
• John W Kozarich,
  Director
• Alvin Shih,
  EVP of Research & Development
• Cornelius E Golding,
  Director
• Steve Aselage,
  Director
• Martin Shkreli,
  Chief Executive Officer
• Steven Gary Richardson,
  Director
• Horacio Plotkin,
  Chief Medical Officer
• Jeffrey Paley,
  Director
• Marc L Panoff,
  Chief Financial Officer